Editorial comparison
Cagrilintide vs semaglutide
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-07-19
These act on two different hormone pathways. Cagrilintide is a long-acting amylin analogue. Semaglutide is a GLP-1 receptor agonist. That is why they have been developed together as a fixed combination rather than as rivals, and it is also why "which is better" is the wrong question. The other difference matters more in practice. Semaglutide is a licensed prescription-only medicine in the UK. Cagrilintide holds no marketing authorisation, is investigational, and cannot lawfully be supplied here for human use.
AI-friendly summary · Cagrilintide vs semaglutide
Cagrilintide is a long-acting amylin analogue and semaglutide is a GLP-1 receptor agonist, so they act on different pathways rather than being alternatives to one another. Semaglutide is licensed in the UK as a prescription-only medicine for weight management, and in July 2026 received a conditional MHRA approval for MASH. Cagrilintide holds no marketing authorisation and is studied largely as half of a fixed-dose combination with semaglutide developed under the name CagriSema. PeptideClear publishes no dosing or human-use guidance for either.
Side by side
| Cagrilintide | Semaglutide | |
|---|---|---|
| Mechanism class | Long-acting amylin analogue | GLP-1 receptor agonist |
| What that means | Amylin is a hormone co-secreted with insulin. An amylin analogue is a different pathway from the incretin pathway, not a variation on it. | GLP-1 is an incretin hormone. A receptor agonist acts at the GLP-1 receptor. |
| UK licensing status | Not licensed. Investigational. | Licensed for weight management, and conditionally approved in July 2026 for MASH in adults with moderate to advanced liver fibrosis. |
| Legal category in the UK | No marketing authorisation. Supply for human use is unlawful. | Prescription-only medicine. |
| How it is usually studied | Largely as one half of a fixed-dose combination with semaglutide, developed under the name CagriSema, rather than on its own. | On its own, across a completed phase 3 programme, and as part of the combination above. |
| Availability in the UK | Not available through any lawful route. Listed by some research-peptide sellers under research-use-only labelling. | Dispensed by registered pharmacies and clinics against a prescription. |
| What a buyer can verify before purchase | Nothing is regulator-verified. At best a seller publishes a batch certificate of analysis from a named third-party lab, which is a transparency signal about the seller and not a safety guarantee. | A licensed product dispensed by a GPhC-registered pharmacy is batch-controlled and the pharmacy is accountable for it. |
Regulatory facts checked against gov.uk on 19 Jul 2026. See the semaglutide UK regulatory status page and the MHRA enforcement and safety tracker.
Why a combination is not two products
Most of what has been published about cagrilintide comes from studying it alongside semaglutide in a fixed-dose combination. That is a deliberate design choice by the developer, because the two act on separate pathways. It also means that findings about the combination are not findings about cagrilintide on its own, and treating them as interchangeable is one of the more common errors in coverage of this compound.
A combination still in development is not a licensed medicine, whatever it is called and however promising the published work looks. Until a regulator has assessed it, there is no UK licensed position to report.
Before you buy anywhere
How to check a weight-loss medicine seller is legitimate
Every GLP-1 weight-management medicine licensed in the UK is prescription-only, so a site that sells you one without a prescriber is supplying illegally. Check the seller on the GPhC register, check the prescriber on the GMC register, and treat a price well under the registered-pharmacy range as a warning rather than a find. The MHRA reported seizing more than 5,000 illegally traded GLP-1 products in 2025 alone.
Frequently asked questions
Is cagrilintide the same kind of drug as semaglutide?
What is CagriSema?
Can I get cagrilintide in the UK?
Is an investigational compound safer because it is "newer"?
Why is there no efficacy comparison on this page?
Check it yourself: the official sources
PeptideClear is editorial. Nothing here replaces the regulator, and you should not take our word for any of it. These are the official UK destinations where the underlying position is published, free to read and open to anyone.
MHRA
MHRA Products portalThe Summary of Product Characteristics and Patient Information Leaflet for every medicine licensed in the UK. This is the authoritative document for what a medicine is licensed to do.
MHRA
Yellow Card schemeReport a suspected side effect, a defective medicine, or a fake or counterfeit product. Anyone can report, including patients. Reports feed the MHRA safety monitoring system.
General Pharmaceutical Council
GPhC registersCheck whether a pharmacy, pharmacist or pharmacy technician is registered in Great Britain. A legitimate UK online pharmacy will appear here.
General Medical Council
GMC registerCheck whether the doctor prescribing for you is registered and licensed to practise in the UK.
NICE
NICE guidanceThe technology appraisals and clinical guidelines that set who is eligible for NHS-funded treatment in England, including for weight-management medicines.
NHS
NHS weight-management informationThe NHS patient-facing explanation of weight-management treatment and how to access it through the NHS.